Researchers looked specifically at head-to-head randomized clinical trials of next-in-class cancer drugs against existing agents in the same class. Less than one-quarter of next-in-class cancer drugs ...

A new study headed by teams at the Wellcome Sanger Institute, EMBL’s European Bioinformatics Institute (EMBL-EBI), and Open Targets has indicated how mutations that cause cancer drug resistance fall ...

Retrospective study finds link between blockbuster drugs and longer survival ...

Thanks to modern therapies, a cancer diagnosis is no longer an automatic death sentence. But many patients still suffer from ...

China’s National Medical Products Administration (NMPA) has approved four new drugs developed by local biopharma companies, including a first-of-its-kind molecule in blood cancer. Wednesday, Chinese ...

A leading oncologist proposes classifying metastatic cancer by molecular alterations rather than organ origin, arguing that the shift could accelerate drug access.

The October 2024 approval of inavolisib for advanced breast cancer spotlighted a growing problem in breast oncology: Managing the hyperglycemia caused by phosphoinositide 3-kinase (PI3K)/Akt pathway ...